Table 2.

Phase III studies on intravenous dose-dense paclitaxel.

Study	Regimen	n	Median PFS  (m)	Median  OS   (m)	Adverse effects	Comments
Katsumata et al., 2009 [21]   Katsumata et al., 2013 [22]   Harano et al., 2014 [23]	JGOG 3016	631			(i) Haematological toxicity higher in dose dense-21.1 versus 9.4%	Lower treatment completion in dose-dense 63 versus 48%  Frequent episodes of delay in dose-dense 76 versus 67%  Dose reductions in dose-dense 48 versus 35%  No significant difference in overall QOL between both groups (p = 0.46)
	Paclitaxel 80 mg/m2 D1, 8, 15 + carboplatin AUC 6, 3 weekly versus   Paclitaxel 180 mg/m2 + carboplatin AUC 6, 3 weekly	312	28.2	100.5
	Both given for 6–9 cycles	319	17.5	62.2
Chan et al., 2013 [24]	GOG-262				(i) Higher frequency of grade 3 anaemia (40.8 versus 15.7%, p < 0.001),  grade 2 sensory neuropathy (25.9 versus 17.8%, p = 0.012) but lower incidence of neutropenia (72 versus 83%, p < 0.001)
	Paclitaxel 80 mg/m2 D1, 8, 15 + carboplatin AUC 6, 3 weekly versus   Paclitaxel 175 mg/m2 + carboplatin AUC 6, 3 weekly	346	14.8	NR
	Both given for 6 cycles	346	14.3	NR
	Bevacizumab given optionally	112   (did not receive bevazicumab)	14.2 vs 10.3
Pignata et al., 2014 [25]	MITO-7	810			(i) Lower incidence of grade 3-4 neutropenia (42 versus 50%), febrile neutropenia (<1 versus 3%, p = 0.02), thrombocytopenia (1 versus 7%, p < 0.001), and other nonhaematological toxicities such as alopecia, vomiting, renal dysfunction, and neuropathy	Quality of life better in dose dense arm (p < 0.0001)
	Paclitaxel 60 mg/m2, weekly + carboplatin AUC 2, weekly versus   Paclitaxel 175 mg/m2 + carboplatin AUC 6, 3 weekly	406 404	18.3  17.3	77∗  79∗

n: number of patients, m: months, D: day PFS: progression free survival, OS: overall survival, NA: not available in paper or abstract, and NR: not yet reached.

^∗Survival rate at 2 years.